Finanzwire Finanzwire
Basculer en Français
9529 Companies
187448 Keywords
119476 Articles
100195 Press releases
Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA Remove
  1. Home
  2. Companies
  3. ORPHAN SYNERGY EUROPE-PHARMA
Finanzwire
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 05/22/2024 at 07:35, 1 year 6 months ago

    OSE Immunotherapeutics and Boehringer Ingelheim Expand Collaboration for Novel Treatments

    Collaboration Immunotherapy Cancer Cardio-renal-metabolic
  • PRESS RELEASE

    published on 05/22/2024 at 07:30, 1 year 6 months ago

    OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases

    OSE Immunotherapeutics and Boehringer Ingelheim expand partnership to develop first-in-class therapies for cancer and cardio-renal-metabolic diseases, aiming to address unmet patient needs
    Partnership Cancer Boehringer Ingelheim OSE Immunotherapeutics First-in-class Treatments
    Logo of ORPHAN SYNERGY EUROPE-PHARMA
  • PRESS RELEASE

    published on 05/26/2023 at 08:15, 2 years 6 months ago

    OSE Immunotherapeutics (OSE): Re-initiation – Milestones anticipated throughout FY23

    Logo of ORPHAN SYNERGY EUROPE-PHARMA
Previous page
1 ... 4 5
Accesswire
  • Published on 12/15/2025 at 16:35, 1 hour 16 minutes ago

    Stillwater Critical Minerals Announces Upsize of Bought Deal LIFE Private Placement for Gross Proceeds of C$15 Million

  • Published on 12/15/2025 at 15:00, 2 hours 51 minutes ago

    Kingfisher Reports Annual General Meeting Voting Results

  • Published on 12/15/2025 at 15:00, 2 hours 51 minutes ago

    Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

  • Published on 12/15/2025 at 14:30, 3 hours 21 minutes ago

    Unusual Machines Congratulates Customers Selected for the Army's PBAS Tranche 1.1, Including Envision Technology and Strategic Logix

  • Published on 12/15/2025 at 14:00, 3 hours 51 minutes ago

    Dateline Delivers Further High-Grade Intercepts from North Pipe at Colosseum

View all ACCESSWIRE
EQS Group
  • Published on 12/15/2025 at 17:45, 5 minutes ago

    EQS-Adhoc: Airbus SE: Airbus reports share buybacks for week starting 8 December 2025

  • Published on 12/15/2025 at 17:38, 12 minutes ago

    Stabilus SE approves share buyback program with a volume of up to €20 million

  • Published on 12/15/2025 at 17:36, 14 minutes ago

    EQS-Adhoc: Stabilus SE approves share buyback program

  • Published on 12/15/2025 at 17:15, 35 minutes ago

    His Highness Sheikh Mansour bin Zayed Al Nahyan Launches "Al Khail Square" at Abu Dhabi Equestrian Club

  • Published on 12/15/2025 at 17:05, 45 minutes ago

    Gensyn Launches $AI Token Sale on Sonar

View all EQS
Les Echos
  • Published on 12/15/2025 at 17:40, 11 minutes ago

    LISI joins the SBF 120 and CAC Mid 60 indices

  • Published on 12/15/2025 at 17:35, 16 minutes ago

    DISCLOSURE OF TRANSACTIONS IN OWN SHARES FROM DECEMBER 8 TO DECEMBER 12, 2025

  • Published on 12/15/2025 at 11:50, 6 hours ago

    Statement about the number of shares composing the share capital and the number of voting rights as of November 30, 2025

  • Published on 12/12/2025 at 18:00, 2 days 23 hours ago

    Disclosure of trading in own shares between November 24th and November 28th, 2025

  • Published on 12/12/2025 at 09:15, 3 days 8 hours ago

    CHANGE IN THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE

With finanzwire.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

Finanzwire

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

© 2025 Finanzwire

Contact Authors Cookies policy Terms and conditions Privacy policy